Abstract: The present invention relates to DNA vaccines that are capable of generating a protective immune response in mammals against a pox virus, and comprises at least one DNA plasmid capable of expressing a plurality of VACV MV antigens, and at least one DNA plasmid capable of expressing a plurality of VACV EV antigens. Also, the present invention relates to methods of inducing a protective immune response in a mammal to pox virus, including a neutralizing antibody response, comprising: injecting into tissue of said mammal said DNA vaccine.
Type:
Application
Filed:
May 28, 2009
Publication date:
December 10, 2009
Applicants:
VGX PHARMACEUTICALS, INC., THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
Inventors:
Ruxandra Draghia-Akli, Jon Prigge, Niranjan Y. Sardesai, David B. Weiner, Lauren A. Hirao
Abstract: There are provided methods of generating antibodies in a mammal against recombinant antigens using DNA plasmids capable of expressing said antigens in cells of said mammal, comprising: injecting into tissue of said mammal a DNA plasmid comprising an encoding sequence operably linked to a promoter, electroporating said tissue with an electroporation device capable of delivering an electrical pulse effective to electroporate cells of said tissue to allow entry of said DNA plasmid and expression of said antigen, and allowing said mammal to respond to said expressed antigen in order to generate antibodies to said antigen. Furthermore, there are provided methods of isolating antibodies specific against desired antigens wherein said antibodies are generated in a mammal using DNA plasmids capable of expressing said antigens.
Abstract: One aspect of the current invention is a method designing and using species-specific or synthetic signal peptides and GHRH sequences for the purpose of preventing and/or treating chronic illness in a subject by utilizing methodology that administers a single dose of nucleic acid expression vector or nucleic acid expression construct encoding a GHRH or functional biological equivalent to a subject through a parenteral route of administration.
Abstract: A composition and a method of increasing growth hormone (“GH”) values in a canine or dog, and more specifically, a canine- or dog-specific growth hormone releasing hormone (“dGHRH”), or functional biological equivalent thereof. The dGHRH is an isolated composition or a nucleic acid molecule that encodes the dGHRH or functional biological equivalent. Also, a method for delivering the composition of this invention to a subject, wherein the dGHRH increases the level of growth hormone (“GH”) secretion in a recipient subject, such as a canine or dog.
Abstract: A composition and a method of increasing growth hormone (“GH”) values in a canine or dog, and more specifically, a canine- or dog-specific growth hormone releasing hormone (“dGHRH”), or functional biological equivalent thereof. The dGHRH is an isolated composition or a nucleic acid molecule that encodes the dGHRH or functional biological equivalent. Also, a method for delivering the composition of this invention to a subject, wherein the dGHRH increases the level of growth hormone (“GH”) secretion in a recipient subject, such as a canine or dog.
Abstract: One aspect of the current invention is an optimized synthetic mammalian expression plasmid (e.g. pAV0201). This new plasmid comprise a therapeutic element, and a replication element. The therapeutic element of the new plasmid comprises a eukaryotic promoter; a 5? untranslated region (“UTR”); a codon-optimized-eukaryotic therapeutic gene sequence; and a poly adenylation signal. The therapeutic elements of this plasmid are operatively linked and located in a first operatively-linked arrangement. Additionally, the optimized synthetic mammalian expression plasmid comprises replication elements, wherein the replication elements are operatively linked and located in a second operatively-linked arrangement. The replication elements comprise a selectable marker gene promoter, a ribosomal binding site, and an origin of replication. The first-operatively-linked arrangement and the second-operatively-linked arrangement comprise a circular structure of the codon optimized synthetic mammalian expression plasmid.
Type:
Grant
Filed:
July 15, 2003
Date of Patent:
January 8, 2008
Assignee:
VGX Pharmaceuticals, Inc.
Inventors:
Ruxandra Draghia-Akli, Ronald V. Abruzzese, Douglas R. Kern
Abstract: Pharmaceutical compositions for and methods of preventing infection or treating an individual who has been identified as being infected with a Flavivirus, Pestivirus, picornovirus or coronavirus such as HCV, GB virus B, JEV, WNV, CSFV, BDV, BVDV, poliovirus, FMDV, or EMCV, comprising administering to the individual a therapeutically effective amount of one or more glucocorticoid receptor antagonist compounds, wherein said compound has steroidal structure are disclosed.
Abstract: Pharmaceutical composition comprising compounds and/or compositions useful to inhibit HIV replication are disclosed. Methods of treating individuals infected with HIV are disclosed. Methods of preventing HIV infection in high risk individuals are disclosed.